Mission Statement, Vision, & Core Values (2026) of Beijing Strong Biotechnologies, Inc.

Founded in 2001, Beijing Strong Biotechnologies, Inc. (BSBE) has grown into a leading Chinese manufacturer of in‑vitro diagnostic (IVD) products-spanning clinical biochemistry reagents and coagulation kits-and partners with global names like Abbott, Roche, Hitachi, Mindray and Weigo to amplify its technology and reach; with a market capitalization of about 7.74 billion CNY as of December 2025 and a workforce of over 1,000, BSBE grounds its operations in the mission "Quality first," delivering diversified, user‑friendly testing solutions, nationwide after‑service support, and a vision to scale domestic leadership into broader international impact while upholding core values of Loyalty, Integrity and Passion that drive continuous R&D, collaboration and customer‑centric excellence-read on to explore how these pillars translate into measurable strategy, products and market momentum

Beijing Strong Biotechnologies, Inc. (300406.SZ) - Intro

Beijing Strong Biotechnologies, Inc. (300406.SZ) is a leading Chinese manufacturer and provider of in-vitro diagnostic (IVD) products, founded in 2001. The company produces a broad portfolio-most notably biochemistry reagents and coagulation products-and serves both domestic and international clinical laboratories, hospitals, and distributors. Strategic partnerships with global diagnostic leaders and a workforce exceeding 1,000 staff underpin its operational capacity and market reach.

• Established: 2001
• Listing/Ticker: 300406.SZ
• Core product lines: biochemistry reagents, coagulation reagents, IVD consumables and instruments
• Strategic partners: Abbott, Roche, Hitachi, Mindray, Weigo
• Market capitalization (Dec 2025): ~7.74 billion CNY
• Employees: >1,000

Mission

• Deliver high-quality, reliable IVD products to improve clinical diagnostic accuracy and patient outcomes.
• Advance accessible diagnostics through scalable manufacturing, robust quality systems, and collaborative partnerships.
• Support healthcare systems with cost-effective reagents and solutions that meet international standards.

Vision

• To be a globally respected IVD innovator, recognized for technological excellence and strong industry alliances.
• Achieve sustained growth that positions Beijing Strong Biotechnologies as a top-tier supplier across Asia and select international markets.

Core Values

• Quality First - stringent QC and compliance with clinical and regulatory standards.
• Innovation - continuous R&D investment to expand reagent and platform capabilities.
• Partnership - fostering long-term collaborations with multinational OEMs and clinical partners.
• Integrity - transparent governance, ethical business conduct, and patient-centered focus.
• Operational Excellence - efficient manufacturing, supply chain resilience, and scalable processes.

Strategic Priorities & KPIs

• Scale production capacity for high-demand reagent lines to capture domestic hospital procurement and export opportunities.
• Deepen technology collaborations (e.g., co-development, OEM supply) with partners such as Abbott and Roche to access advanced assay platforms.
• Maintain and grow market capitalization and investor confidence via consistent financial performance and transparent reporting; current market cap is ~7.74 billion CNY (Dec 2025).
• Talent and quality metrics: sustain workforce >1,000 with continued investment in QC, regulatory affairs, and clinical validation teams.

For a financial-focused deep dive and investor-oriented metrics, see: Breaking Down Beijing Strong Biotechnologies, Inc. Financial Health: Key Insights for Investors

Beijing Strong Biotechnologies, Inc. (300406.SZ) - Overview

• Beijing Strong Biotechnologies, Inc. (300406.SZ) is firmly committed to the mission of 'Quality first,' prioritizing the delivery of high-quality diagnostic products and services across clinical settings.
• The company provides comprehensive testing solutions covering clinical biochemistry and serology to ensure accurate and reliable results for hospitals, laboratories, and point-of-care users.
• BSBE offers diversified clinical diagnostic solutions that address a wide spectrum of disease areas and testing scenarios, from routine screening to specialized assays.
• BSBE is dedicated to a user-friendly experience: products are designed for ease of operation, clear result interpretation, and streamlined workflows for end-users.
• The company has established an after-service network across the country to guarantee prompt issue resolution and professional technical support for customers.
• The mission underscores BSBE's strategic focus on quality, customer satisfaction, broad diagnostic coverage, and sustained service capability.

• To be a leading provider of reliable diagnostic solutions domestically and a recognized partner in global laboratory medicine by continuously improving quality, expanding product breadth, and advancing reproducibility and accessibility.
• To integrate innovation, regulatory compliance, and service excellence so that diagnostic decisions are faster, more accurate, and widely accessible.

• Quality Assurance - rigorous manufacturing and QC processes to maintain high analytical performance and product stability.
• Customer Centricity - fast technical support, training, and service commitments tailored to clinical needs.
• Innovation - sustained investment in R&D to expand assay panels and platform capabilities.
• Integrity & Compliance - meeting regulatory and ethical standards in product registration, clinical validation, and post-market surveillance.
• Collaboration - partnerships with clinical laboratories, distributors, and research institutions to extend reach and improve clinical value.

• Comprehensive pre-sales consultation to align platform selection with laboratory throughput and clinical needs.
• On-site installation, user training, and validation support to accelerate clinical adoption and reduce time-to-result for facilities.
• Multi-tiered after-service system: remote diagnostics, field engineers, spare parts logistics, and scheduled preventive maintenance to minimize downtime.

• Manufacturing follows defined quality management practices to ensure batch-to-batch consistency and traceability throughout production.
• Products undergo clinical verification and stability testing; post-market surveillance mechanisms capture user feedback and adverse event data to drive continuous improvement.

Beijing Strong Biotechnologies, Inc. (300406.SZ) - Mission Statement

• Market leadership: sustain and grow market share in core segments (rapid tests, immunoassays, POCT) with target segment shares above national averages.
• International expansion: deepen strategic partnerships and distribution channels across Asia, Europe, Africa and the Americas to increase exports and overseas revenue.
• Innovation pipeline: continuously expand R&D outputs to address emerging infectious diseases, chronic disease markers and digital diagnostics.
• Collaborations: strengthen tech and commercialization alliances with domestic research institutes and selected global enterprises to accelerate product development and regulatory approvals abroad.
• Customer excellence: maintain high product quality and after-sales service metrics, aiming for top-quartile satisfaction and repeat-purchase rates in served markets.

• Product leadership - accelerate launch cadence: target 20-30 new product registrations across key markets within the next 3 years, prioritizing high-demand markers and rapid diagnostics.
• Global partnerships - leverage alliances: form co-development and distribution agreements with selected global enterprises to pursue joint regulatory filings and scale manufacturing for export markets.
• Manufacturing scale & quality - expand capacity: optimize GMP production lines and automation to support export volumes while maintaining ISO/CE/CFDA (NMPA) compliance.
• R&D and digital integration - invest in next-gen diagnostics: allocate a sustained portion of revenue to develop molecular POCT, multiplex assays and digital reporting solutions.
• Customer-centric operations - enhance service: implement CRM and training programs to improve customer retention and time-to-adoption in hospitals and point-of-care settings.

• Deepen distribution ties in target regions to convert the 80+ country footprint into sustained revenue streams and regulatory footholds.
• Pursue co-development projects with international diagnostic leaders to access advanced assay platforms and accelerate CE/IVD/other filings.
• Leverage local partnerships for market access, regulatory navigation and after-sales support to improve time-to-market and adoption.

• Maintain strict quality controls across manufacturing sites and supply chains, supported by ISO, NMPA and CE certifications where applicable.
• Deploy training, technical support and digital resources for clinical users to improve diagnostic accuracy and product utilization.
• Target customer retention improvement and increased average order value through bundled product-service offerings.

Beijing Strong Biotechnologies, Inc. (300406.SZ) - Vision Statement

• Loyalty - to patients, clinicians, partners, and investors, prioritizing long-term relationships over short-term gains.
• Integrity - transparent governance, regulatory compliance, and accountable reporting across operations and supply chains.
• Passion - a relentless drive to improve diagnostic accuracy, reduce time-to-result, and expand access to underserved markets.
• Excellence - continuous quality improvement in R&D, manufacturing, and customer support to meet stringent clinical standards.
• Collaboration - partnering with hospitals, academic institutions, and global distributors to scale impact.
• Innovation - sustained investment in research and development to push the boundaries of point-of-care and laboratory diagnostics.

• R&D intensity: allocating a material portion of revenue to product advancement and regulatory submissions.
• Quality systems: implementing ISO and regulatory frameworks to ensure product safety and market acceptance.
• Partnership strategy: co-development and licensing to accelerate market entry and broaden product portfolios.

• KPIs: product approval timelines, time-to-market for new assays, customer satisfaction scores, and recurring revenue percentage.
• Governance: audit-ready financials, ethical procurement, and transparent disclosure to investors and regulators.
• Stakeholder engagement: structured collaborations with clinical partners to validate clinical utility and broaden adoption.